Scholar Rock Holding Corp SRRK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Gets FDA Approval of Isembyld for Spinal Muscular Atrophy
-
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
-
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
-
Scholar Rock to Present at Upcoming Investor Conferences
-
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $46.81
- Day Range
- $42.47–47.19
- 52-Week Range
- $27.07–61.76
- Bid/Ask
- $43.46 / $44.00
- Shares Outstanding
- 121.79M
- Market Cap
- $5.29B
- Volume/Avg
- 3M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 289
- Website
- https://www.scholarrock.com
Valuation
|
Metric
|
SRRK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 22.43 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SRRK
|
|---|---|
Quick Ratio | 6.84 |
Current Ratio | 7.02 |
Interest Coverage | −38.47 |
Quick Ratio
SRRK
Profitability
|
Metric
|
SRRK
|
|---|---|
Return on Assets (Normalized) | −74.41% |
Return on Equity (Normalized) | −131.46% |
Return on Invested Capital (Normalized) | −85.46% |
Return on Assets
SRRK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$qk$t$@ | LOCK|!B&@q | $128B | |||
| Moderna Inc
MRNA
| LOCK|BmHR>fg | LOCK|>p^ | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|MJjbKJ | LOCK|@b@t | $76B | |||
| argenx SE ADR
ARGX
| LOCK|!!m>$M | LOCK|V^ | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>yrj!X | LOCK|Z@V | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|lF!c<^ | LOCK|?^t%y | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|M&w$X!<$ | LOCK|#?m$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|gZz>L@S | LOCK|@!> | $24B | |||
| Incyte Corp
INCY
| LOCK|sKz?yq | LOCK|r$Y | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&R@@DS | LOCK|%? | $15B |
United States